"Who's going to pay price to bring back manufacturing in US", asks Biocon MD
Advertisement
New Delhi: Siddharth Mittal, the CEO and Managing Director of Biocon Limited, raised a critical question on Friday, asking who would bear the cost of relocating their establishments to the United States, where production expenses are significantly higher compared to India and China.
Speaking at the Carnegie Global Technology Summit, Siddharth Mittal said, "I think we all know that manufacturing for all segments moved to China, which was a cost arbitrage over decades. And now you're trying to reverse it. So, there's a price to pay."
"And in our industry, I'll give you an example, that if a drug in is made at X price in China, it's 1.25 to 1.3 X in India. And the analysis we have done is if we have to do the same thing in the US, it's going to be 2X. So, who's going to pay the price to bring back manufacturing in the US?" he asked.
According to ANI, he said 50 percent of the drugs in the US come from India, indicating that the US is a key market for Indian pharmaceutical products. Most Indian companies have set up manufacturing plants in the US.
"US is biggest market for us, but it is very price sensitive. The US has a great research ecosystem. We have the talent, and India has a good understanding of the entire ecosystem. US, of course, has a great research ecosystem, and I think that's where I see a first opportunity," he said.
He also spoke about the dependence of China on active pharma ingredients.
"India is still dependent 70 per cent on China to procure starting materials or raw materials. So if we do not address the entire value chain, we will not fix the problem," he supplemented.
Earlier, on April 9, while speaking at the National Republican Congressional Committee dinner, US President Donald Trump warned of impending tariffs on Pharma.
"Tariffs on pharma will be there because we don't make our own pharma drugs; they are made in another country. The same packet in the US is priced at USD 10 or more. We are going to tariff pharma in such a way that companies will come rushing to us very soon. The advantage we have is, we are very big market. Very shortly, will announce a major tariff on pharma, and when these companies hear that, they will leave China and other countries because most of their products are sold here. And they will be opening their plants here," Trump said.
Indian generic drug manufacturers play a significant role in the U.S. healthcare system, supplying nearly 40 percent of the generic drugs imported into the country. In FY24, Indian pharmaceutical exports to the U.S. were valued at approximately USD 8 billion, with the industry witnessing an 8 percent compound annual growth rate (CAGR) over FY15 -24
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.